Advanced search
Publication Cover
Vascular Health and Risk Management Volume 6, 2010 - Issue
Submit an article Journal homepage
87
Views
6
CrossRef citations to date
0
Altmetric
Review

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

Curtis TriplittDiabetes Division, Department of Medicine, University of Texas, Health Science Center at San Antonio, and the Texas Diabetes Institute, San Antonio, Texas, USA
,
Eugenio CersosimoDiabetes Division, Department of Medicine, University of Texas, Health Science Center at San Antonio, and the Texas Diabetes Institute, San Antonio, Texas, USA
&
Ralph A DeFronzoDiabetes Division, Department of Medicine, University of Texas, Health Science Center at San Antonio, and the Texas Diabetes Institute, San Antonio, Texas, USACorrespondence[email protected]
Pages 671-690 | Published online: 05 Aug 2010

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Brian Tomlinson, Paul Chan & Christopher Wai Kei Lam. (2022) An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 23:1, pages 29-42.
Read now
André J Scheen. (2015) Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 1005-1020.
Read now
Kishore VL Parsa & Manojit Pal. (2011) Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview. Expert Opinion on Drug Discovery 6:8, pages 855-869.
Read now
Thomas Forst, Markolf Hanefeld & Andreas Pfützner. (2011) Review of approved pioglitazone combinations for type 2 diabetes. Expert Opinion on Pharmacotherapy 12:10, pages 1571-1584.
Read now

Articles from other publishers (2)

Yury O. Nunez Lopez, Anna Casu, Zuzana Kovacova, Alejandra M. Petrilli, Olga Sideleva, William G. Tharp & Richard E. Pratley. (2022) Coordinated regulation of gene expression and microRNA changes in adipose tissue and circulating extracellular vesicles in response to pioglitazone treatment in humans with type 2 diabetes. Frontiers in Endocrinology 13.
Crossref
Yuan-Jie Wu, Yuan-Bo Wu, Zhao-Hui Fang, Mei-Qiao Chen, Yu-Feng Wang, Chuan-Yun Wu & Ming-An Lv. (2019) Danzhi Jiangtang Capsule Mediates NIT-1 Insulinoma Cell Proliferation and Apoptosis by GLP-1/Akt Signaling Pathway. Evidence-Based Complementary and Alternative Medicine 2019, pages 1-7.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.